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Pegylated-asparaginase during induction therapy for adult
acute lymphoblastic leukaemia: toxicity data from the
UKALL14 trial
B Patel1, AA Kirkwood2, A Dey3, DI Marks4, AK McMillan5, TF Menne6, L Micklewright2, P Patrick2, S Purnell2, CJ Rowntree7,
P Smith2 and AK Fielding3
Safety and efﬁcacy data on pegylated asparaginase (PEG-ASP) in adult acute lymphoblastic leukaemia (ALL) induction regimens are
limited. The UK National Cancer Research Institute UKALL14 trial NCT01085617 prospectively evaluated the tolerability of 1000 IU/
m2 PEG-ASP administered on days 4 and 18 as part of a ﬁve-drug induction regimen in adults aged 25–65 years with de novo ALL.
Median age was 46.5 years. Sixteen of the 90 patients (median age 56 years) suffered treatment-related mortality during initial
induction therapy. Eight of the 16 died of sepsis in combination with hepatotoxicity. Age and Philadelphia (Ph) status were
independent variables predicting induction death440 versus ⩽ 40 years, odds ratio (OR) 18.5 (2.02–169.0), P=0.01; Ph− versus Ph+
disease, OR 13.60 (3.52–52.36), Po0.001. Of the 74 patients who did not die, 37 (50.0%) experienced at least one grade 3/4 PEG-
ASP-related adverse event, most commonly hepatotoxicity (36.5%, n= 27). A single dose of PEG-ASP achieved trough therapeutic
enzyme levels in 42/49 (86%) of the patients tested. Although PEG-ASP delivered prolonged asparaginase activity in adults, it was
difﬁcult to administer safely as part of the UKALL14 intensive multiagent regimen to those aged 440 years. It proved extremely
toxic in patients with Ph+ ALL, possibly owing to interaction with imatinib.
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INTRODUCTION
Depletion of extracellular asparagine by parenteral administration
of the enzyme L-asparaginase is a key component of most current
therapeutic strategies in acute lymphoblastic leukaemia (ALL). In
children, intensive L-asparaginase treatment, typically delivered by
pegylated Escherichia coli-derived L-asparaginase (PEG-ASP),
improves clinical outcome,1–6 offering a longer half-life7 and a
lower risk of antiasparaginase antibody formation. Safety and
efﬁcacy is less well established in older adults,8,9 and toxicity can
be substantial10—in a phase 2 trial, failure to deliver the intended
doses was closely correlated with advancing age.11
UKALL14 (NCT01085617) is an on-going, multicentre, phase 3
study that addresses several questions in the treatment of
newly diagnosed adult ALL. A major study aim is to evaluate
the addition of two doses of 1000 IU/m2 PEG-ASP to the standard
induction regimen that had been evaluated in our previous study,
UKALL12,12 in which non-pegylated E. coli L-asparaginase was
given at 10 000 IU daily on days 17–28 of phase 1 induction.
The only other change to the ‘backbone’ induction regimen
between the two consecutive national trials was the addition of a
steroid prephase and the substitution of pulsed dexamethasone
for prednisolone. The aim of these changes was to make our
regimen more compatible with a 'paediatric-inspired' intensive
approach.
The overall end point of the trial is event-free survival. However,
a speciﬁc end point of the PEG-ASP evaluation is toxicity related
to PEG-ASP. Secondary end points include rate of complete
remission (CR), overall survival, minimal residual disease (MRD)
quantitation at the end of the ﬁrst phase of induction and
antiasparaginase antibody formation. Here we report on
the outcome of PEG-ASP administered during induction in the
ﬁrst consecutive 91 trial subjects. At this point, it was judged
by the trial management group that a toxicity end point
had been reached and a change was made to the PEG-ASP
trial therapy.
MATERIALS AND METHODS
UKALL14 induction phase 1 treatment
Eligible patients were aged ⩾ 25 and ⩽ 65 years with newly diagnosed ALL,
irrespective of Philadelphia (Ph) chromosome status. There was no
exclusion for poor organ function or performance status at diagnosis.
Ethical approval was obtained from the UK National Research Ethics
Committee. All patients gave written, informed consent, according to the
Declaration of Helsinki. Patients received a 5–7-day prephase
of dexamethasone 6 mg/m2/day followed by two sequential courses of
induction therapy, termed induction phase 1 and induction phase 2,
respectively. Patients with precursor B lineage ALL were randomised
to receive chemotherapy alone or chemotherapy plus four doses of
rituximab given on day (D) 3, D10, D17 and D24, PEG-ASP 1000 IU/m2
on D4 and D18, daunorubicin 60 mg/m2 and vincristine 1.4 mg/m2
(2 mg max.) on D1, D8, D15 and D21, dexamethasone 10 mg/m2 D1,
−D4, D8–D11 and D15–D18 and a single 12.5 mg intrathecal methotrexate
dose on D14. Patients with Ph chromosome-positive (Ph+) disease
received continuous oral imatinib from D1, starting at 400 mg and
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escalating to 600 mg given daily throughout induction. Antibacterial,
antiviral and antifungal prophylaxis was mandated, but centres used
local policy for choice of agents. Granulocyte colony-stimulating
factor support was strongly recommended. Routine antithrombotic
prophylaxis was suggested but not mandated for all patients with
platelet counts 450 × 109/l. Anticoagulation with antithrombin replace-
ment was recommended in the case of thrombosis. Routine coagulation
factor replacement for laboratory-detected coagulopathy was speciﬁ-
cally discouraged.
All patients had an initial assessment of response—including MRD
response by BCR-ABL transcript monitoring or clonal immunoglobulin
(Ig)/T-cell receptor gene rearrangement quantiﬁcation—at the end of
induction phase 1, which did not affect treatment decision. Formal
assessment of response to induction therapy (outside the scope of this
report) was documented after phase 2 induction.
A simpliﬁed schema of the remainder of UKALL14 treatment is provided
in Figure 1.
Causality assessment for toxicity and death
The standard Common Terminology Criteria for Adverse Events (CTCAE)
reporting system (http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/ctc.htm) was used. Causality of events was attributed, as is
standard practice, by both the local site Principal Investigator and the
central study clinical team. Additional detailed questionnaires and Principal
Investigator's narratives were received for all induction deaths allowing a
more detailed analysis of individual events.
PEG-ASP antibody assays
Antibodies against PEG-ASP (IgG and IgE) were measured by two indirect
enzyme-linked immunosorbent assays, which detected anti-PEG-ASP and
non-pegylated anti-E. coli (non-pegylated asparaginase). Seroconversion
was reported with positivity in at least one assay with a clearly negative
predose sample. Anti-asparaginase antibody ratio over negative control
41.1 was used to deﬁne positivity.
Serum asparaginase activity by MAAT testing
PEG-ASP enzyme activity was quantiﬁed in sera using the MAAT7 assay.
Therapeutic enzyme levels were deﬁned as 4100 IU/l.
Statistical analysis
Induction phase 1 treatment-related death was deﬁned as any death
occurring before the start of phase 2 induction where the cause of death
was not primarily attributable to progressive ALL. Logistic regression was
used to examine risk potential factors for induction death and grade 3/4
adverse events (AEs). Factors with a conservative Po0.2 in the univariate
analysis were included in the multivariable analyses. All analyses were
conducted using Stata 14.0 (Stata Corporation, College Station, TX, USA).
Non-fatal grade III–IV AEs causally related to PEG-ASP were those classiﬁed
as probably or deﬁnitely related. All AEs were graded according to CTCAE
version 4.0.
RESULTS
Patient characteristics
Ninety-one eligible patients (from 37 centres) were enrolled
onto UKALL14 between 30 December 2010 and 19 April 2012.
One patient died before starting any treatment and has been
excluded from all analyses. Patient characteristics at diagnosis
are summarised in Table 1. The majority (59 of 90, 66%)
of patients were aged440 years and nearly a third (26/90, 29%)
had Ph+ ALL. Most patients (92%) had performance scores of
0–1 at diagnosis. Median follow-up was 36.0 months (12 days–
50.4 months).
Induction deaths
Progress through the induction therapy blocks is shown in
Figure 2. Among those commencing phase 1 induction therapy
(n = 90), there were 18 early deaths. Two patients died of
progressive ALL and the other 16 (16/90, 18%) deaths were
related to induction treatment, occurring at a median time from
start to induction of 23 days (range 10–53).
The causes of induction deaths are summarised in Table 2. In 12
of the 16 (75%), the causes of death were most often multi-
factorial; sepsis together with hepatotoxicity occurred in 8 of 16,
50.0%. Neutropenic sepsis alone occurred in 3 of the 16 patients,
(18.8%). A causative organism was identiﬁed in 11 of the cases of
sepsis, with a Gram-negative bacterial infection being responsible
in 8 of those. Additional causes of death were: hepatotoxicity plus
bowel ischaemia (n= 2), acute coronary syndrome plus neutro-
penic sepsis (n= 1), hepatotoxicity plus pancreatitis (n= 1), and
pulmonary haemorrhage (n= 1). Nine of the 11 hepatotoxicity-
related induction deaths were associated with grade 3–4
hyperbilirubinaemia. In total, half of the induction deaths were
accompanied by recognised PEG-ASP toxicities (namely, those
Figure 1. Schematic of UKALL14 treatment protocol. High risk features: karyotypes: t(9;22) t(4;11), low hypodiploidy near triploidy or complex,
age440 years, WBC ⩾ 30× 109/l (precursor B lineage ALL), ⩾ 100 × 109/l (T-cell-ALL), molecular minimal residual disease positivity (41 × 10− 4)
after induction phase 2.
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already listed in the Summary of Product Characteristics
as occurring in 1:⩾ 1000 patients, or less common but
clearly recognised as being related to PEG-ASP). There was no
obvious association between baseline comorbidities and
induction death.
All patients received D4 PEG-ASP. Sixty-four, including 5 of
the 16 who suffered induction deaths, received the second
dose on D18. For patients who died during induction, the
median time from last dose of PEG-ASP to death was 13 days
(range 6–50).
Risk factors for induction death
Table 3 shows a univariate analysis of factors predictive of
induction death. Age, Ph positivity and high-risk cytogenetics
were all risk factors. Patients aged over 40 years had a more than
10-fold increase in risk of death during induction with Ph+ disease
conferring a more than 8-fold increase compared with
Ph− disease (odds ratio (OR): 8.65 (2.61–28.71), Po0.001). There
was no relationship to baseline albumin levels or body mass index
(BMI). The data monitoring committee also conﬁrmed that there
was no relationship to rituximab randomisation arm. The multi-
variable analysis is also shown in Table 3. Although high-risk
cytogenetics appeared to be associated with induction death, this
was driven by the presence of t(9;22), so this factor alone was
included in the multivariable analysis. Age and Ph status remained
signiﬁcantly associated with induction death; in patients who were
Ph− , there were no deaths in the 21 patients aged ⩽ 40 years and
5 in the 43 patients aged440 years. In patients with Ph+ ALL, 1 of
the 10 patients aged ⩽ 40 years died compared with 10 of the 16
who were aged 440 years.
AEs during phase 1 induction therapy
Including the patients discussed above who subsequently
died, 87 of the 91 patients (97%) experienced a grade 3–5 AE
during induction phase 1; among these 46 (51%) suffered one or
more recognised PEG-ASP toxicities; 34 had grade 3–5 AEs
indicating liver dysfunction, including 22 with raised bilirubin.
Other PEG-ASP toxicities included pancreatitis (n = 3), intracra-
nial haemorrhage (n = 1), allergic reaction (n = 3), coagulation
disorder (n = 4) and vascular events (n= 6). Thirty-seven of the 74
surviving patients (50.0%) experienced at least one recognised
grade 3–4 PEG-ASP-related, non-fatal toxicity summarised in
Table 4. Hepatotoxicity—including biochemical markers of liver
dysfunction—was the most frequent PEG-ASP-related toxicity
(36.5%, n= 27). Venous thromboembolism (4.1%, n = 3), allergic
reaction (4.1%, n= 3) and pancreatitis (2.7%, n = 2) were all
reported but were relatively uncommon. A complete line-listing
of all AE/serious AE as well as the subset known to be
recognised toxicities of PEG-ASP from which Table 4 is derived
is given in Supplementary Supplementary Table S1. As liver
toxicity was so prominent and can be a key determinant of
subsequent on-time therapy delivery, an analysis of any
pretreatment factors associated with grade 3–4 hepatotoxicity
was carried out. This is shown in Table 5. Older age and BMI
were the only factors that showed a signiﬁcant association (OR:
2.88 (1.62–15.44), P= 0.005, for patients aged 440 years
compared with those ⩽ 40 years and OR: 1.58 (1.02–2.44),
P= 0.041, for a 5 unit increase in BMI).
Asparaginase activity, antiasparaginase antibody formation and
correlation with MRD response
A trough level of asparaginase activity by MAAT testing7,13 was
assessed 14 days after the ﬁrst (D4) PEG-ASP dose in 49 patients in
whom serum was available (n= 49). Therapeutic activity (enzyme
level 4100IU/l) was achieved in 42 of 49 (86%). The median
enzyme level in those achieving therapeutic enzyme levels was
234 IU/l (range 101.5–602.8) as compared with 44.8IU/l (0–97.5)
in those with subtherapeutic levels. There was no evidence of an
association between age and achievement of therapeutic enzyme
level. Molecular MRD at the end of phase 1 induction was
documented in 27 patients. Molecular remission rates did not
signiﬁcantly differ between those achieving therapeutic enzyme
levels of PEG-ASP and those who did not (14/26 compared with
Table 1. Patient characteristics at diagnosis
Characteristic N (%)
Lineage
B-precursor 77 (86)
T-cell 13 (14)
Sex
Male 48 (53)
Female 42 (47)
Age at entry (years)
Median (range) 46.50 (25–65)
⩾ 55 29 (32)
⩾ 41 59 (66)
Presenting WBC (×109/l)
Median (range) 9.26 (0.52–297.4)
o30 62 (69)
30–99.9 15 (17)
100+ 13 (14)
Cytogenetic risk status
High riska 28 (31)
Low risk 42 (47)
Unknownb 20 (22)
t(9;22)
Absent 64 (71)
Present 26 (29)
Low hypodiploidy/near triploidy
Absent 65 (72)
Present 4 (4)
Failed/missing 21 (23)
t(4;11)
Absent 75 (83)
Present 7 ( 8)
Failed/missing 8 (9)
Complex karyotype
Absent 64 (71)
Present 5 (6)
Failed/missing 21 (23)
Performance status
0 55 (61)
1 28 (31)
2 5 ( 6)
3 1 (1)
Missing 1 (1)
BMI
Normal/underweightc 31 (34)
Overweight 25 (28)
Obese 34 (38)
Abbreviations: BMI, body mass index; WBC, white blood cell. aHigh risk:
t(9;22), t(4;11) low hypodiploidy/near triploidy or complex karyotypes.
bNo high-risk factors and at least one risk factor is missing or failed. c30 in
the normal range and 1 patient with a BMI of 17.
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3/4), suggesting that an early complete molecular response in this
setting is not contingent upon therapeutic asparaginase enzyme
activity. Anti-PEG-ASP antibody formation at D18 was assessed in
59 patients, and at that time point, there were no instances of
seroconversion.
DISCUSSION
Successful achievement of CR during induction therapy for
ALL is an absolute prerequisite for long-term disease-free
survival. Numerous previous studies have suggested that
induction regimens typically used in children give a better
Figure 2. Flow chart of progress of the 91 patients enrolled. Grade 4 sepsis n= 4, grade IV organ toxicity n= 4 (hepatotoxicity n= 1,
pancreatitis n= 1, hepatotoxicity plus neurological event n= 1, hepatotoxicity plus thromboembolism together with sepsis n= 1 and wrong
diagnosis n= 1, withdrawal of consent, n= 1.
Table 2. Summary of deaths during induction
ID Patient details Comorbidities Hepatotoxicity
(grade)
Neutropenic sepsis
(organism)
Haemorrhage
(site)
Thrombosis/
visceral
ischaemia (site)
Pancreatitis Other PEG-ASP
doses
Days from last
PEG-ASP dose
1003 Age 54 years PH− Liver
cirrhosis
4 Not known D4 and 18 19
1004 Age 46 years PH+ None Pseudomonas
aeruginosa
Acute coronary
syndrome
D4 16
1011 Age 43 years PH+ None 4 Escherichia coli Renal failure D4 & 18 8
1021 Age 65 years PH− None 4 Pseudomonas
aeruginosa
Gastrointestinal D4 50
1026 Age 64 years PH+ Depression 4 Pseudomonas
aeruginosa
D4 20
1028 Age 38 years PH+ None Enterococcus faecium D4 15
1029 Age 60 years PH+ IHD 4 Escherichia coli D4 14
1030 Age 49 years PH+ None Pulmonary D4 6
1039 Age 62 years PH+ None 2 Small bowel D4 10
1043 Age 63 years PH− Grade 4
renal failure
4 Klebsiella
pneumoniae
Carotid artery
puncture site
D4 and D18 43
1049 Age 56 years PH+ None 4 Pseudomonas
aeruginosa
D4 11
1057 Age 57 years PH− None 4 Small bowel D4 20
1061 Age 54 years PH+ Paroxysmal
atrial
ﬁbrillation
3 Yes GI perforation D4 10
1063 Age 62 years PH+ None Coagulase-negative
staph/Enterococcus
faecium
D4 and D18 12
1068 Age 64 years PH+ None 4 Respiratory syncytial
virus
Renal failure D4 21
2007 Age 55 years PH− None Pseudomonas
aeruginosa
D4 and D18 8
Abbreviations: IHD, ischaemic heart disease; PEG-ASP, pegylated asparaginase.
Toxicity during UKALL14 induction therapy for ALL
B Patel et al
4
Leukemia (2016) 1 – 7
outcome for teenagers and younger adults than typical ‘adult’
regimens.14–18 As a consequence, there is general acceptance
of testing the outcome of increasing the intensity of non-
myelosuppressive agents such as PEG-ASP in regimens used for
older adults.
Within the ﬁrst 91 patients enrolled, we noted signiﬁcantly greater
induction mortality in UKALL14 than in our previous trial, UKALL12.
Induction death occurred in 16 of the ﬁrst 90 (17.8%) treated
patients, and 15 of the ﬁrst 59 (25%) participants being aged 440
years (10/29 (33%) being aged 455 years). The median age of the
patient population enrolled in this period was 46.5 years, with 29%
of patients being aged 455 years. By comparison, the induction
death rate in our previous trial, UKALL12/ECOG2993, was 6%
overall (ages 15–60 years, median age 36 years)12 and 15% in the
55–65-year range (median age 56 years).19 UKALL14 did not
exclude any patient with poor organ function or comorbidity at
diagnosis, but we did not ﬁnd any evidence of these factors
having a causal contribution to PEG-ASP-related mortality.
Analysis of the cause of each death in UKALL14 included a
complete written narrative from the treating physician as well as
the standard case report forms for serious AE collection. Bacterial
sepsis was revealed as a major contributor to the deaths. However,
concomitant grade 3–4 PEG-ASP toxicities were very common
among those suffering induction death, such that a recognised
PEG-ASP toxicity was associated with half of the 16 induction deaths.
It is impossible to disentangle the role of the investigational
medicinal product (IMP) PEG-ASP from that of concomitant non-IMP
induction agents. However, the introduction of dexamethasone
instead of prednisolone was the only change that had been made to
the standard backbone regimen between UKALL12 and UKALL14.
It is noteworthy that most of the induction deaths reported here
occurred after an early, single (D4) dose of PEG-ASP, any toxicity of
which would overlap with the myelosuppressive toxicity of
anthracycline administered on D1, D8, D15 and D22. The 60 mg/
m2 dose of anthracycline given in the UKALL12 regimen was well
tolerated, but asparaginase was not started until D17. The earlier
addition of PEG-ASP-associated liver dysfunction to subsequent
myelosuppression-related sepsis may have been responsible for
the overlapping toxicity. The fact that sepsis was a major
contributor to the mortality supports that contention.
To date, only two other studies reporting the use of PEG-ASP
speciﬁcally in adults have been published, both of which report a
lower dose and/or different schedule of anthracycline. A phase 2
trial CALGB 9511(ref. 11) reported on 102 adults treated with PEG-
ASP at 2000 U/m2 subcutaneously, capped at 3750 U/m2, starting
on D5 of the ﬁve-drug induction regimen. Although the regimen
was reported to be 'tolerable', bilirubin 451.3 μM (3 mg/dl)
occurred in 54% of patients. CR rate was only 77% but induction
deaths are not separated from induction failures within the report.
There was a statistically signiﬁcant difference in median age of
those achieving full dose delivery and asparagine depletion—32
years versus 48 years. In a more recent study from Douer et al.20 in
51 adults median age 32 years, upper age limit 57 years reported
no deaths directly as a result of PEG-ASP in regimen, which
included 2000 IU/m2 PEG-ASP given on D15. However, 3 of the 51
(6%) patients died of neutropenic sepsis during consolidation. In
this case, daunorubicin was given at 60 mg/m2 intravenously on
D1–D3. Grade 3–4 hyperbilirubinaemia (1/3 patients) or transami-
nitis (2/3 of patients) was very common. Douer et al.20 also
reported long median intervals from PEG-ASP to bilirubin
recovery, which affected subsequent chemotherapy delivery.
The younger median age of patients in that study, the small
number receiving concurrent imatinib (N= 5), a more modest
anthracycline dose and different scheduling of PEG-ASP admin-
istration so as not to coincide with the maximal myelosuppression
may all have contributed to the difference in toxicity.
The German Multicentre Adult ALL Group have reported in
abstract form21 on 1000 adult patients aged 15–55 years, treated
on the German 07/2003 study in which a single dose of 1000–
2000 U/m2 PEG-ASP was administered on D3 during induction
with a reported rate of induction death rate of o5% and a
grade IV hyperbilirubinaemia incidence of 16%. As with the
study by Douer et al.,20 the younger median age (35 years) of the
cohort in addition to the lower dose of anthracycline (45 versus
the 60 mg/m2 used in the current study) may underpin the
differences in toxicity.
Table 3. Univariate and multivariate analysis of risk factors for induction death
Risk factor Events/n Univariable Multivariable
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Age, years
⩽ 40 1/31 1.00 0.03 18.50 (2.02–169.0) 0.01
440 15/59 10.23 (1.28–81.59)
Gender
Male 8/48 1.00 0.77 — —
Female 8/42 1.18 (0.40–3.47)
Baseline WBC per × 109/l increment 16/90 1.00 (0.99–1.01) 0.56 —
Cytogeneticsa
Standard risk 2/28 1.00 0.0029 — —
High risk 13/42 5.83 (1.20–28.29)
Ph
Absent 5/64 1.00 o0.001 13.60 (3.53–52.36) o0.001
Present 11/26 8.65 (2.61–28.71)
Base albumin (g/l) (10 unit increment) 16/90 1.03 (0.40–2.64) 0.95 — —
Base bilirubin (μmol/l) (10 unit increment) 16/90 0.91 (0.59–1.42) 0.69 — —
BMI (5 unit increment) 16/90 1.29 (0.82–2.02) 0.27 — —
Abbreviations: BMI, body mass index; CI, conﬁdence interval; WBC, white blood cell. aAnalysed as no high-risk factors versus high-risk Ph and high-risk Ph+
gives HRs of 1.86 (0.24–14.64) and 9.53 (1.86–49.91), respectively.
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It should be noted that the French GRAAALL group also
reported that advancing age resulted in a higher cumulative
incidence of chemotherapy-related deaths (23% versus 5%,
respectively; Po0.001) and deaths in ﬁrst CR (22% versus 5%,
respectively; Po0.001) during 'paediatric-style' therapy, even
when non-pegylated asparaginsae was used. In the study reported
by Huguet et al.,22 ⩾ 45 years of age was the strongest predictor of
severe toxicity,
As a consequence of the toxicity reported here, the UKALL14
protocol was amended to omit D4 PEG-ASP for those aged 440
years. Furthermore, PEG-ASP was completely removed from
induction treatment for all patients with Ph+ ALL. In addition,
owing to the high level of sepsis related to profound myelosup-
pression, the daunorubicin dose was halved to 30 mg/m2 on D1,
D8, D15 and D22. One year following this amendment, when an
additional 302 further patients had been recruited with 244
patients assessable for induction death, a repeat analysis showed
only 6 (2.5%) phase 1 induction deaths (data not shown).
Univariate analysis demonstrated that older age and poor-risk
cytogenetics—including t(9;22)—were signiﬁcantly associated
with induction death. On multivariable analysis, age and Ph
positivity remained as independent risk factors for induction
death, suggesting that the concomitant imatinib therapy only
received by those with Ph+ ALL may have compounded the
potential for PEG-ASP toxicity. The precise mechanism by which
this might occur is not known. However, from the Summary of
Product Characteristics for imatinib, ‘increased hepatic enzymes’ is
reported as common (1:10 to 1:100), hyperbilirubinaemia occurs in
between 1:100 and 1:1000 patients and, ﬁnally, hepatic failure is
noted as ‘rare’, namely, occurring between 1:1000 and 1:10 000
cases. Hence, the potential for overlapping hepatotoxicity of PEG-
ASP and imatinib is clearly present.
Half of the patients who did not experience an induction death
experienced one or more grade 3–4 PEG-ASP toxicities from which
they eventually recovered—most commonly, hepatotoxicity.
Twenty-three percent of patients in this study experienced grade
⩾ 3 hyperbilirubinaemia; by deﬁnition, a limitation or exclusion to
further dosing with many commonly used ALL therapeutics. On
analysis of treatment delays in our previous trial, UKALL12/E2993
study showed that delays of 44 weeks were associated with
poorer overall survival and event-free survival in patients under-
going allogeneic hematopoietic stem cell transplantation but not
in patients undergoing postremission chemotherapy.22 Any long-
term impact of any delays engendered by toxicity during initial
induction therapy in this study will become clear when the trial is
completed and we can evaluate any delays in relation to our
primary end point, event-free survival.
Our pharmacokinetic studies indicate that a single dose of
1000 IU/m2 PEG-ASP generates therapeutic enzyme levels in most
patients—86% of assessable patients had therapeutic levels of
PEG-ASP activity 14 days after administration. A recent long-
itudinal analysis of PEG-ASP pharmacokinetics during a ‘paediatric’
regimen in adult ALL demonstrated therapeutic enzyme activity in
a similar proportion of adult patients for up to 21 days.20 In our
Table 4. Patients who did not die during induction: summary of the
grade 3/4 AEs recognised in SPC as being related to PEG-ASPa
SOC/event term Grade 3+ PEG-ASP known AEs,
N (%)
Gastrointestinal disorders 2 (3)
Pancreatitis 2 (3)
Hepatobiliary disorders 3 (4)
Liver failure 1 (1)
Liver dysfunction 2 (3)
Immune system disorders 3 (4)
Allergic reaction 3 (4)
Investigations 29 (39)
Lipase increased 1 (1)
Serum amylase increased 3 (4)
Alkaline phosphatase increased 15 (20)
Aspartate aminotransferase
increased
4 (5)
Blood bilirubin increased 17 (23)
Alanine aminotransferase
increased
10 (14)
GGT increased 5 (7)
Metabolism and nutrition disorders 3 (4)
Increased triglycerides 1 (1)
Hypoalbuminaemia 2 (3)
Nervous system disorders 1 (1)
Intracranial haemorrhage 1 (1)
Vascular disorders 4 (5)
Pulmonary embolism 1 (1)
Thromboembolic event 3 (4)
Non-CTCAE terms
Coagulation disorder 3 (4)
Any liver event 27 (36)
Any toxicity 37 (50)
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria;
GGT, gamma glutamyl transpeptidase; PEG-ASP, pegylated asparaginase;
SPC, Summary of Product Characteristics; SOC, System Organ Class.
aA complete line listing of grade 3+ AE/serious AE according to CTCAE
criteria with assignment of causality by both site and by trial management
group is provided in Supplementary Table S1.
Table 5. Analysis of risk factors for liver-related grade 3/4 adverse
events during phase 1 induction in patients who did not have an
induction death
Risk factor Grade 3/4 liver AEs
Events/n Odds ratio
(95% CI)
P-value
Age
⩽ 40 5/30 1.00 0.005
440 22/44 2.9 (1.62–15.44)
Sex
Male 16/40 1.00 0.50
Female 11/34 0.72 (0.28–1.87)
Baseline WBC per × 109/l
increment
27/74 1.00 (0.99–1.01) 0.71
Cytogenetics
Standard risk 10/26 1.00 0.97
High risk 11/29 0.98 (0.33–2.91)
Ph
Absent 20/59 1.00 0.36
Present 7/15 1.71 (0.54–5.38)
Base albumin (g/l) (10 unit
increment)
27/74 0.89 (0.41–1.92) 0.77
Base bilirubin (μmol/l) (10 unit
increment)
27/74 1.02 (0.81–1.30) 0.86
BMI (5 unit increment) 27/74 1.58 (1.02–2.44) 0.041
Abbreviations: AE, adverse event; BMI, body mass index; CI, conﬁdence
interval; WBC, white blood cell.
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study, antiasparaginase antibodies were not seen at the early time
point documented.
In conclusion, we have shown that PEG-ASP achieves very
effective asparagine depletion without antiasparaginase antibody
formation in the majority of adult patients. However, toxicity can
be substantial in older patients, making a 'paediatric-inspired'
regimen of the type commonly used used in paediatric and young
adult therapy difﬁcult to deliver safely to those aged 440 years.
Avoidance of overlapping toxicities and careful timing of
administration will be of key importance to the more widespread
use of this type of regimen in older adults.
As remission can be induced with minimal mortality in patients
with Ph+ ALL,23,24 we suggest that PEG-ASP is never coadminis-
tered with imatinib during induction therapy.
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